Effects of salmeterol on skeletal muscle cells: Metabolic and proapoptotic features

Medicine and Science in Sports and Exercise

Volumn 43, Issue 12, 2011, Pages 2259-2273

  Duranti, Guglielmo ^a   La Rosa, Piergiorgio ^a   Dimauro, Ivan ^a   Wannenes, Francesca ^b   Bonini, Sergio ^b,c   Sabatini, Stefania ^a   Parisi, Paolo ^a   Caporossi, Daniela ^a  

^a UNIVERSITY OF ROME FORO ITALICO   (Italy)

^b INSTITUTE OF TRANSLATIONAL PHARMACOLOGY   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Ar agonists; apoptosis; C2C12; L6C5; Smac DIABLO

Indexed keywords

3 HYDROXYACYL COENZYME A DEHYDROGENASE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CASPASE 9; CITRATE SYNTHASE; DRUG DERIVATIVE; GLYCERALDEHYDE 3 PHOSPHATE PHOSPHATASE; GLYCERALDEHYDE 3-PHOSPHATE PHOSPHATASE; LACTATE DEHYDROGENASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OXYGEN; PHOSPHATASE; PROTEIN BCL X; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; SALBUTAMOL; SALMETEROL;

ANIMAL; APOPTOSIS; ARTICLE; CELL LINE; CELL PROLIFERATION; DRUG EFFECT; HUMAN; METABOLISM; MOUSE; RAT; SKELETAL MUSCLE;

3-HYDROXYACYL COA DEHYDROGENASES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ALBUTEROL; ANIMALS; APOPTOSIS; BCL-X PROTEIN; CASPASE 9; CELL LINE; CELL PROLIFERATION; CITRATE (SI)-SYNTHASE; HUMANS; L-LACTATE DEHYDROGENASE; MICE; MUSCLE, SKELETAL; OXYGEN; PHOSPHORIC MONOESTER HYDROLASES; POLY(ADP-RIBOSE) POLYMERASES; RATS; TRANSGLUTAMINASES;

EID: 81355147799     PISSN: 01959131     EISSN: 15300315     Source Type: Journal    
DOI: 10.1249/MSS.0b013e3182223094     Document Type: Article

References (43)

1. Berridge MV, Tan AS. Characterization of the cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction. Arch Biochem Biophys. 1993;303(2):474-82. (Pubitemid 23199849)
2. Brodde OE. A1-and A2-adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. Pharmacol Rev. 1991;43:203-42.
3. Burniston JG, Chester N, Clark WA, Tan LB, Goldspink DF. Dose-dependent apoptotic and necrotic myocyte death induced by the A2-adrenergic receptor agonist, clenbuterol. Muscle Nerve. 2005;32:767-74. (Pubitemid 41746265)
4. Burniston JG, Tan LB, Goldspink DF. A2-adrenergic receptor stimulation in vivo induces apoptosis in the rat heart and soleus muscle. J Appl Physiol. 2005;98:1379-86. (Pubitemid 40396514)
5. Caporossi D, Ciafre SA, Pittaluga M, Savini I, Farace MG. Cellular responses to H(2)O(2) and bleomycin-induced oxidative stress in L6C5 rat myoblasts. Free Radic Biol Med. 2003; 35:1355-64. (Pubitemid 37452461)
6. Catani MV, Savini I, Duranti G, et al. Nuclear factor JB and activating protein 1 are involved in differentiation-related resistance to oxidative stress in skeletal muscle cells. Free Radic Biol Med. 2004;37:1024-36. (Pubitemid 39164584)
7. Cross F, Roberts J, Weintraub H. Simple and complex cell cycles. Annu Rev Cell Dev Biol. 1989;5:341-95. (Pubitemid 19286688)
8. Delbeke FT, Desmet N, Debackere M. The abuse of doping agents in competing body builders in Flanders (1988-1993). Int J Sports Med. 1995;16:66-70.
9. Dumestre-Toulet V, Cirimele V, Ludes B, Gromb S, Kintz P. Hair analysis of seven bodybuilders for anabolic steroids, ephedrine, and clenbuterol. J Forensic Sci. 2002;47:211-4. (Pubitemid 34084180)
10. Essen-Gustavsson B, Henriksson J. Enzyme levels in pools of microdissected human muscle fibres of identified type. Adaptive response to exercise. Acta Physiol Scand. 1984;120:505-15. (Pubitemid 14139067)
11. Goldstein DR, Dobbs T, Krull B, Plumb VJ. Clenbuterol and anabolic steroids: a previously unreported cause of myocardial infarction with normal coronary arteriograms. South Med J. 1998; 91:780-4. (Pubitemid 28374537)
12. Gorczyca W, Gong J, Darzynkiewicz Z. Detection of DNA strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidyl transferase and nick translation assays. Cancer Res. 1993;53:1945-51. (Pubitemid 23127129)
13. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid: Allen & Hanburys Limited UK Study Group. Lancet. 1994;344:219-24. (Pubitemid 24229008)
14. Greer EL, Oskoui PR, Banko MR, et al. The energy sensor AMPactivated protein kinase directly regulates the mammalian FOXO3 transcription factor. J Biol Chem. 2007;282:30107-19. (Pubitemid 350035296)
15. Gross DN, van den Heuvel AP, Birnbaum MJ. The role of FoxO in the regulation of metabolism. Oncogene. 2008;27:2320-36. (Pubitemid 351501783)
16. Hagstrom-Toft E, Enoksson S, Moberg E, Bolinder J, Arner P. Aadrenergic regulation of lipolysis and blood flow in human skeletal muscle in vivo. Am J Physiol. 1998;275:E909-16.
17. Harada H, Grant S. Apoptosis regulators. Rev Clin Exp Hematol. 2003;7:117-38. (Pubitemid 37466216)
18. Harper JM, Mackinson I, Buttery PJ. The effects of A agonists on muscle cells in culture. Domest Anim Endocrinol. 1990;7(4):477-84.
19. Hoeks J, van Baak MA, Hesselink MK, et al. Effect of A1-and A2-adrenergic stimulation on energy expenditure, substrate oxidation, and UCP3 expression in humans. Am J Physiol Endocrinol Metab. 2003;285:E775-82. (Pubitemid 37176428)
20. Jackson MJ, Pye D, Palomero J. The production of reactive oxygen and nitrogen species by skeletal muscle. J Appl Physiol. 2007;102:1664-70. (Pubitemid 46571066)
21. Johnson M. A2-adrenoceptors: mechanisms of action of A2-agonists. Paediatr Respir Rev. 2001;2:57-62.
22. Johnson M. The A-adrenoceptor. Am J Respir Crit Care Med. 2002;158:S146-53.
23. Lippi G, Franchini M, Favaloro EJ, Guidi GC. Salbutamol in athletes. Clin J Sport Med. 2008;18(5):469.
24. Lynch GS, Ryall JG. Role of A-adrenoceptor signaling in skeletal muscle: implications for muscle wasting and disease. Physiol Rev. 2008;88:729-67. (Pubitemid 351520091)
25. Maklashina E, Ackrell BAC. Is defective electron transport at the hub of aging? Aging Cell. 2004;3:21-7. (Pubitemid 40246658)
26. Martin WH, Murphree SS, Saffitz JE. A-adrenergic receptor distribution among muscle fiber types and resistance arterioles of white, red and intermediate skeletal muscle. Circ Res. 1989;64:1096-105. (Pubitemid 19155780)
27. Martinez FD. Safety of long-acting A-agonists-an urgent need to clear the air. N Engl J Med. 2005;353:2637-9. (Pubitemid 41817711)
28. Nevzorova J, Bengtsson T, Evans BA, Summers RJ. Characterization of the A-adrenoceptor subtype involved in mediation of glucose transport in L6 cells. Br J Pharmacol. 2002;137:9-18. (Pubitemid 34983459)
29. Owen K, Beck SL, Damment SJ. The preclinical toxicology of salmeterol hydroxynaphthoate. Hum Exp Toxicol. 2010;29(5): 393-407.
30. Ryall JG, Sillence MN, Lynch GS. Systemic administration of A2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses. Br J Pharmacol. 2006;147:587-95.
31. Salih DA, Brunet A. FoxO transcription factors in the maintenance of cellular homeostasis during aging. Curr Opin Cell Biol. 2008; 20:126-36.
32. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-analysis: effect of long-acting A-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med. 2006;144: 904-12. (Pubitemid 46768131)
33. Silvestri M, Fregonese L, Sabatini F, Dasic G, Rossi GA. Fluticasone and salmeterol downregulate in vitro, fibroblast proliferation and ICAM-1 or H-CAM expression. Eur Respir J. 2001;18: 139-45. (Pubitemid 32717441)
34. Spurlock DM, McDaneld TG, McIntyre LM. Changes in skeletal muscle gene expression following clenbuterol administration. BMC Genomics. 2006;7:320.
35. Stensrud T, Berntsen S, Carlsen KH. Exercise capacity and exercise-induced bronchoconstriction (EIB) in a cold environment. Respir Med. 2007;101(7):1529-36. (Pubitemid 46832223)
36. Stewart AG, Tomlinson PR, Wilson JW. A2-adrenoceptor agonist-mediated inhibition of human airway smooth muscle cell proliferation: importance of the duration of A2-adrenoceptor stimulation. Br J Pharmacol. 1997;121:361-8. (Pubitemid 27226285)
37. Sultan KR, Henkel B, Terlou M, Haagsman HP. Quantification of hormone-induced atrophy of large myotubes from C2C12 and L6 cells: atrophy-inducible and atrophy-resistant C2C12 myotubes. Am J Physiol Cell Physiol. 2006;290:C650-9.
38. Sundal S, Sharma S. Ultrastructural findings for the mitochondrial subpopulation of mice skeletal muscle after adrenergic stimulation by clenbuterol. J Physiol Sci. 2007;57:7-14. (Pubitemid 46974936)
39. Tan RA, Spector SL. Exercise-induced asthma. Sports Med. 1998;25:1-6. (Pubitemid 28031860)
40. The World Anti-Doping Agency Web site [Internet]. The 2011 Prohibited List. International Standard [cited 2010 Sept 18, effective 2011 Jan 1]. Available from: http://www.wada-ama.org.
41. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science. 1998;281:1312-6. (Pubitemid 28406817)
42. Tomlinson PR, Wilson JW, Stewart AG. Inhibition by salbutamol of the proliferation of human airway smooth muscle cells grown in culture. Br J Pharmacol. 1994;111:641-7. (Pubitemid 24146125)
43. Wong K, Boheler KR, Bishop J, Petrou M, Yacoub MH. Clenbuterol induces cardiac hypertrophy with normal functional, morphological and molecular features. Cardiovasc Res. 1998;37:115-22. (Pubitemid 28122623)